Glucose Homeostasis – Mechanism and Defects by Leszek Szablewski
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Glucose Homeostasis – Mechanism and Defects 
Leszek Szablewski 
Medical University of Warsaw 
Poland 
1. Introduction 
Glucose is an essential metabolic substrate of all mammalian cells. D-glucose is the major 
carbohydrate presented to the cell for energy production and many other anabolic 
requirements. Glucose and other monosaccharides are transported across the intestinal wall 
to the hepatic portal vein and then to liver cells and other tissues. There they are converted 
to fatty acids, amino acids, and glycogen, or are oxidized by the various catabolic pathways 
of cells. 
Most tissues and organs, such as the brain, need glucose constantly, as an important source 
of energy. The low blood concentrations of glucose can causes seizures, loss of 
consciousness, and death. On the other hand, long lasting elevation of blood glucose 
concentrations, can result in blindness, renal failure, vascular disease, and neuropathy. 
Therefore, blood glucose concentrations need to be maintained within narrow limits. The 
process of maintaining blood glucose at a steady-state level is called glucose homeostasis. 
This is accomplished by the finely hormone regulation of peripheral glucose uptake, heaptic 
glucose production and glucose uptake during carbohydrate ingestion. This maintenance is 
achieved through a balance of several factors, including the rate of consumption and 
intestinal absorption of dietary carbohydrate, the rate of utilization of glucose by peripheral 
tissues and the loss of glucose through the kidney tubule, and the rate of removal or release 
of glucose by the liver and kidney. To avoid postprandial hyperglycemia (uncontrolled 
increases in blood glucose levels following meals) and fasting hypoglycemia (decreased in 
blood glucose levels during periods of fasting), the body can adjust levels by a variety of 
cellular mechanisms. Important mechanisms are conveyed by hormones, cytokines, and fuel 
substrates and are sensed through of cellular mechanisms. 
Diabetes mellitus is one of the clinical manifestations of long-term metabolic abnormalities 
involving multiple organs and hormonal pathways that impair the body’s ability to 
maintain glucose homeostasis. As a result of impaired glucose homeostasis is a 
hyperglycemia. Prolonged elevation of blood glucose concentrations causes a number of 
complications like blindness, renal failure, cardiac and peripheral vascular disease, 
neuropathy, foot ulcers, and limb amputation. Vascular complications represent the leading 
cause of mortality and morbidity in diabetic patients. 
Hypoglycemia is abnormally low levels of sugar (glucose) in the blood. Low levels of sugar 
in the blood interfere with the function of much organ system. A person with hypoglycemia 
may feel weak, drowsy, confused, hungry, and dizzy. The other signs of low blood sugar 
are: paleness, headache, irritability, trembling, sweating, rapid heart beat, and a cold. The 
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most common cause of hypoglycemia is a complication of diabetes. Low level of glucose in 
the blood occurs most often in people who use insulin to lower their blood sugar. 
Hypoglycemia can occur as a side effect of some oral diabetes medication that increases 
insulin production. People with diabetes who reduce food intake to lose weight are more 
likely to have hypoglycemia.  
2. Role of glucose in mammalian cells metabolism 
2.1 Glucose as a source of cellular energy 
Glucose is rapidly metabolized to produce ATP (adenosine triphosphate), a high energy end 
product. Glucose is oxidized through a large series of reactions that extract the greatest 
amount of possible energy from it. If glucose metabolism occurs in the presence of oxygen 
(aerobically), the net production are 36 molecules of ATP from one molecule of glucose, and 
2 molecules of ATP, if glucose metabolism occurs in the absence of oxygen (anaerobically). 
For details see [Szablewski, 2011]. 
2.1.1 Glycolysis 
Glycolysis is the first pathway which begins the complete oxidation of glucose to pyruvate. 
It takes place in the cytoplasm of the cell. Glycolysis occurs virtually in all tissues. This 
pathway is unique in the sense that it can proceed in both aerobic and anaerobic conditions. 
Glycolysis is the pathway which cleaves the six carbon glucose molecule into two molecules 
of the three carbon compound pyruvate. The end result of glycolysis is two molecules of 
ATP and two molecules of NADH+H+ (Nicotinamide adenine dinucleotide – reduced form). 
NAD is used as an electron acceptor. This cofactor is present only in limited amounts and 
once reduced to NADH+H+, as in this reaction, it must be re-oxidized to NAD to permit 
continuation of the pathway. This process occurs by the one of the two methods: aerobic 
metabolism of glucose or anaerobic glycolysis. 
2.1.2 Oxidative decarboxylation  
During aerobic metabolism of glucose in the mitochondria, pyruvate is oxidized. During 
this reaction NAD is uses as an electron and proton acceptor, and pyruvate is converted to 
acetyl coenzyme-A (abbreviated as “acetyl-CoA”). The carboxyl group of pyruvate leaves 
the molecule as CO2 and the remaining two carbons become acetyl-CoA. This reaction 
occurs twice since each glucose (six carbons) produce 2 pyruvates (three carbons each). 
Consequently, these processes produce 2 NADH+H+, 2 Acetyl-CoA, and 2 CO2. 
2.1.3 Krebs cycle 
Further series of reactions, all which occur inside mitochondria (mitochondrial matrix) of 
eukaryotic cells, is collectively called “Krebs Cycle”, also known as the “Citric Acid Cycle” 
or the “Tricarboxylic Acid Cycle”. In this cycle, acetyl-CoA is oxidized ultimately to CO2. It 
is to note, that the molecules that are produced in these reactions can be used as building 
blocks for a large number of important processes, including the synthesis of fatty acids, 
steroids, cholesterol, amino acids, and the purines and pyrimidines. Fuel for Krebs cycle 
comes from lipids, carbohydrates, and proteins, which produce the molecule acetyl-CoA. 
While the Krebs cycle does produce CO2, this cycle does not produce significant chemical 
energy in the form of ATP directly. This cycle produces NADH+H+ and FADH2, which feed 
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into the respiratory cycle, also located inside mitochondria (inner mitochondrial membrane). 
It is electron transport chain that is responsible for production of large quantities of ATP. 
The electron transport chain converts NADH+H+ and FADH2 into reactants that the Krebs 
cycle requires to function. If oxygen is not present, the electron transport chain cannot 
function, which halts the Krebs cycle. 
2.1.4 Electron transport chain 
Oxidative phosphorylation is a series of reactions that utilize the energy from NADH+H+ 
and FADH2 electron carriers to produce more ATP. Embedded in the inner membrane of the 
mitochondria are the series of proteins that use the stored energy from NADH+H+ and 
FADH2 to pump protons into the membrane space. This results in an electrical and chemical 
gradient of protons. The enzyme ATP synthase (ATPase) uses the proton gradient to drive 
the reaction of producing ATP from ADP and inorganic phosphate. The electron transport 
chain consists of a series of proteins (called cytochromes) that are embedded in the inner 
mitochondria membrane and an enzyme ATP synthase. There are four complexes, namely, 
I, II, III, and IV. In complex IV, the electrons are combined with protons and oxygen to form 
water, the final end-product. The oxygen acts as the final electron acceptor and without 
oxygen, soothe reaction does not proceed and therefore only anaerobic respiration is 
possible. The end result of electron transport chain is three molecules of ATP, if a donor of 
protons and electrons is NADH+H+ and one molecule of H2O. If a donor of protons and 
electrons is FADH2, the end result of electron transport chain is two molecules of ATP and 
one molecule of H2O. 
2.1.5 The metabolism of lactate 
The anaerobic glycolysis occurs in the absence of oxygen (anaerobically). During anaerobic 
glycolysis, earlier obtained pyruvate is reduced to a compound called lactate. This reduction 
of pyruvate to lactate is coupled to the oxidation of NADH+H+ to NAD. Glycolysis and 
reduction of pyruvate to lactate are coupled to the net production of two molecules of ATP 
from one molecule of glucose. Accumulation of lactate also causes a reduction in 
intracellular pH. Therefore lactate is removed to other tissues and dealt with by one of the 
two mechanisms: 1) Lactate is converted back to pyruvate. This process is enzymatically 
catalyzed by lactate dehydrogenase. In this reaction, lactate becomes oxidized (loses two 
electrons) and is converted to pyruvate. The pyruvate then proceeds to be further oxidized 
by a second mechanism, the aerobic metabolism of glucose. 2) Conversion of lactate to 
glucose in the process of gluconeogenesis. 
2.2 Gluconeogenesis 
Gluconeogenesis is a metabolic pathway that results in the generation of glucose from non-
carbohydrate carbon substrate such as lactate, glycerol, and glucogenic amino acids. One 
common substrate is lactic acid formed in the skeletal muscle in the absence of oxygen. It 
may also come from erythrocytes, which obtain energy solely from glycolysis. The lactic 
acid is released to the blood stream and transported into liver. Here it is converted to 
glucose. The glucose is then returned to the blood for use by muscle as an energy source and 
to replenish glycogen stores. This cycle is termed the “Cori cycle”. The gluconeogenesis of 
the cycle is net consumer energy, costing the body four moles of ATP more than are 
produced during glycolysis. Therefore, the cycle cannot be sustained indefinitely. The 
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process of gluconeogenesis uses some of the reactions of glycolysis (in reverse direction) and 
some reactions unique to this pathway to re-synthesize glucose. This pathway requires an 
energy input, but has a role of maintaining a circulating glucose concentration in the blood 
stream even in the absence of dietary supply. Fatty acids cannot be converted into glucose in 
animals with the exception of odd-chain acids, which yield propionyl-CoA, a precursor of 
succinyl-CoA. Glycerol, which is a part of all triacylglycerols, can also be used in 
gluconeogenesis. On the other hand, in humans and other mammals, in which glycerol is 
derived from glucose, glycerol is sometimes not considered a true gluconeogenic substrate, 
as it cannot be used to generate new glucose. For details see [Szablewski, 2011]. 
2.3 Glycogenesis 
Glycogenesis is the process of glycogen synthesis in which glucose molecules are added to 
chains of glycogen to storage in liver and muscle. This process acts during rest periods 
following the Cori cycle, in the liver, and also activated by insulin in response to high 
glucose levels. For details see [Szablewski, 2011]. 
2.4 Glycogenolysis 
When the blood sugar levels fall, glycogen stored in the tissue, especially glycogen of 
muscle and liver may be broken down. This process of breakdown of glycogen is called 
“Glycogenolysis” (also known as “Glycogenlysis”). Glycogenolysis occurs in the liver and 
muscle. Hepatocytes can consume glucose-6-phosphate in glycolysis, or remove the 
phosphate group and release the free glucose into the blood stream for uptake by other cells. 
Since muscle cells lack enzyme glucose-6-phosphatase, they cannot convert glucose-6-
phosphate into glucose and therefore use the glucose-6-phosphate for their own energy 
demands. For details see [Szablewski, 2011]. 
2.5 Pentose phosphate pathway 
The pentose phosphate pathway (also called “Phosphogluconate pathway” or “Hexose 
monophosphate shunt”) is primarily a cytoplasmic anabolic pathway that converts the six 
carbons of glucose to five carbons (pentose) sugars and reducing equivalents. The primary 
functions of this pathways are: 1) To generate reducing equivalents (NADH+H+) for 
reductive biosynthesis reactions within cells; 2) To provide the cell with ribose-5-phosphate 
for the synthesis of the nucleotides and nucleic acids; 3) To metabolize dietary pentose 
sugars derived from the digestion of nucleic acids as well as rearrange the carbon skeleton 
of dietary carbohydrates into glycolytic/gluconeogenic intermediates. This pathway is an 
alternative to glycolysis. While it does involve oxidation of glucose, its primary role is 
anabolic rather than catabolic. It is to note, that 30% of the oxidation of glucose in the liver 
occurs via the pentose phosphate pathway. For details see [Szablewski, 2011]. 
2.6 Lipogenesis 
Lipogenesis is the process by which simple sugars such as glucose are converted to fatty 
acids. Lipogenesis starts with acetyl-CoA and builds up by the addition of two carbon units. 
Fatty acids are subsequently esterified with glycerol to form triglycerides that are packed in 
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3. Glucose homeostasis 
3.1 Definition of glucose homeostasis 
Most tissues and organs need glucose constantly, as an important source of energy. The low 
blood concentrations of glucose can cause seizures, loss of consciousness, and death. On the 
other hand, long lasting elevation of glucose concentrations, can result in blindness, renal 
failure, vascular disease etc. therefore, blood glucose concentrations need to be maintained 
within narrow limits. The process of maintaining blood glucose at a steady-state level is 
called “glucose homeostasis” [DeFronzo, 1988]. This is accomplished by the finely hormone 
regulation of peripheral glucose uptake, hepatic glucose production, and glucose uptake 
during carbohydrates ingestion. For details see [Szablewski, 2011]. 
3.2 Mechanisms of glucose homeostasis 
To avoid postprandial hypoglycemia and fasting hypoglycemia, the body can adjust glucose 
levels by secreting two hormones, insulin and glucagon that work in opposition to each 
other. During periods of hyperglycemia, the ǃ-cells of the pancreatic islets of Langerhans 
secrete more insulin. Insulin is synthesized in ǃ-cells of pancreas in response to an elevation 
in blood glucose and amino acid after a meal. The major function of insulin is to counter the 
concerned action of a number of hyperglycemia-generating hormones to maintain low blood 
glucose levels. It also plays an important role in the regulation of glucose metabolism. This 
hormone regulates glucose metabolism at many sites reducing hepatic glucose output, via 
decreased gluconeogenesis and glycogenolysis, facilitates the transport of glucose into 
striated muscle and adipose tissue, and inhibits glucagon secretion. Insulin is not secreted if 
the blood concentration is ≤ 3 mmol/L, but is secreted in increasing amounts as glucose 
concentrations increase beyond this threshold [Gerich, 1993]. When blood glucose levels 
increase over about 5 mmol/L the ǃ-cells increase their output of insulin. The glucagon 
producing ǂ-cells of the pancreatic islets of Langerhans remain quiet, and hold on their 
hormone. It is to note, that postprandially, the secretion of insulin occurs in two phases. An 
initial rapid release of preformed insulin, followed by increased insulin synthesis and 
release in response to blood glucose. Long-term release of insulin occurs if glucose 
concentrations remain high [Aronoff et al., 2004; Cryer, 1992]. On the other hand, during 
periods of hypoglycemia, the ǂ-cells of the pancreatic islets of Langerhans secrete more 
glucagon. It is the principal hormone responsible for maintaining plasma glucose at 
appropriate levels during periods of increased functional demand [Cryer, 2002]. This 
hormone counteracts hypoglycemia and opposes insulin actions by stimulating hepatic 
glucose production. It induces a catabolic effect, mainly by activating liver glycogenolysis 
and gluconeogenesis, which results in the release of glucose to the bloodstream, thereby 
increasing blood glucose levels. The digestion and absorption of nutrients are associated 
also with increased secretion of multiple gut hormones that act on distal targets. There are 
more than 50 gut hormones and peptides synthesized and released from the gastrointestinal 
tract. These hormones are synthesized by specialized enteroendocrine cells located in the 
epithelium of the stomach, small bowel, and large bowel. It was demonstrated that ingest 
food caused a more potent release of insulin than glucose infused intravenously [Perley & 
Kipnis, 1967]. This effect, termed the “incretin effect” suggests that signals from the gut are 
important in the hormonal regulation of glucose disappearance. Incretin hormones are 
peptide hormones secreted from the gut and specific criteria have to be fulfilled for an agent 
to be called an incretin. They have a number of important biological effects, as for example, 
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release of insulin, inhibition of glucagon, maintenance of ǃ-cells mass, and inhibition of 
feeding. Several incretin hormones have been characterized, but currently, GLP-1 
(Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) are the 
only known incretins. Both GLP-1 and GIP are secreted in a nutrient-dependent manner and 
stimulate glucose-dependent insulin secretion. Gut hormones are secreted at low basal 
levels in the fasting state. The secretion of gut hormones is regulated, at least in part, by 
nutrients. Plasma levels of most gut hormones rise quickly within minutes of nutrient 
uptake and fall rapidly thereafter mainly because they are cleared by the kidney and are 
enzymatically inactivated [Drucker, 2007]. 
4. Defects in glucose homeostasis 
4.1 Hyperglycemia 
Hyperglycemia is the technical term for high blood glucose (sugar). It develops when there 
is too much sugar in the blood. High blood glucose happens when the body has too little 
insulin or when the body cannot use insulin properly. Hyperglycemia is a serious health 
problem for those with diabetes. In people with diabetes, there are two specific types of 
hyperglycemia that occur. Fasting hyperglycemia is defined as a blood sugar greater than  
90 – 130 mg/dL (5 – 7.2 mmol/L) after fasting for at least 8 hours. Postprandial (after-meal 
hyperglycemia) is defined as a blood sugar usually greater than 180 mg/dL (10 mmol/L). 
Hyperglycemia in diabetes may be caused by: skipping or forgetting insulin or oral glucose-
lowering medicine, eating too many grams of carbohydrates for the amount of insulin 
administered, eating too much food and having too many calories, infection, illness, 
increased stress, decreased activity or exercising less than unusual, strenuous physical 
activity. Early signs and symptoms of hyperglycemia include the following: increased thirst, 
headaches, difficulty concentrating, blurred vision, frequent urination, fatigue (weak, tired 
feeling), weight loss, blood sugar more than 180 mg/dL (10 mmol/L), high levels of sugar in 
the urine. Prolonged hyperglycemia in diabetes may result in: vaginal and skin infections, 
slow-healing cuts and sores, decreased vision, nerve damage causing painful cold or 
insensitive feet, stomach and intestinal problems. In people without diabetes postprandial 
or post-meal sugars rarely go over 140 mg/dL (7.8 mmol/L), but occasionally, after a large 
meal, a 1 – 2 hour post-meal glucose levels can reach 180 mg/dL (10 mmol/L). Blood 
glucose levels can vary from day to day. An occasional high level (above 10 mmol/L) is not 
problem, as long as it returns to normal (below 7 mmol/L; 126 mg/dL) within 12 – 24 hours. 
Persistently high blood glucose levels (above 15 mmol/L; 270 mg/dL) for more than 12 – 24 
hours can result in the symptoms of hyperglycemia. For details see [Szablewski, 2011]. 
4.1.1 Impaired glucose tolerance and impaired fasting glucose 
There are two forms of pre-diabetes: impaired glucose tolerance (IGT) and impaired fasting 
glucose (IFG). Impaired glucose tolerance is a transition phase between normal glucose 
tolerance and diabetes, also referred to as prediabetes. In impaired glucose tolerance, the 
levels of blood glucose are between normal and diabetic. People with IGT do not have 
diabetes. Each year, only 1 – 5% of people whose test results show IGT actually develop 
diabetes. Weight loss and exercise may help people with IGT return their glucose levels to 
normal. Impaired glucose tolerance is a combination of impaired secretion of insulin and 
reduced insulin sensitivity (insulin resistance). Fasting blood glucose levels are normal or 
moderately raised. IGT is diagnosed when: 1) plasma glucose, two hours after consuming 75 g 
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glucose, appears to be superior to 7.8 mmol/L (normal level) but remains inferior to 11.1 
mmol/L (diabetes level). The level of plasma glucose is measured by means of an Oral 
Glucose Tolerance Test (OGTT). The procedure typically involves testing glucose levels after 
an eight hour fasting period, and measuring it again two hours after drinking a sugar 
solution. Generally, if the test shows blood glucose levels in the 140 and 199 mg/dL range, 
two hours after the drink, this could signify impaired glucose tolerance. 2) Fasting plasma 
glucose is less than 7.0 mmol/L (6.1 – 6.9 mmol/L), a level above normal, but below the 
threshold for diagnosis of diabetes. Impaired glucose tolerance is often affiliated with 
several other similar related risk factors such as high blood pressure (hypertension), 
increased LDL-cholesterol, reduced HDL-cholesterol. A person has impaired fasting glucose 
when fasting plasma glucose is 100 to 125 mg/dL. This level is higher than normal but less 
than the level indicating a diagnosis of diabetes. Diabetes mellitus is characterized by 
recurrent or persistent hyperglycemia and is diagnosed by demonstrating any one of the 
following: fasting plasma glucose level ≥ 7.0 mmol/L (126 mg/dL), plasma glucose ≥ 11.1 
mmol/L (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test, 
symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/dL, glycated 
hemoglobin (HbA1C) ≥ 6.5%. 
4.1.2 Type 1 diabetes mellitus 
Type 1 diabetes mellitus (previously known as juvenile or insulin-dependent diabetes) 
results due to autoimmune progressive destruction of insulin-producing ǃ-cells by CD4+ 
and CD8+ T cells and macrophages infiltrating the islets [Foulis et al., 1991]. Although, the 
etiology of type 1 diabetes is believed to have a major genetic component, studies on the risk 
of developing type 1 suggest that environmental factor may be important etiological 
determinants. Evidence of an autoimmune etiology is found in about 95% of these cases and 
is classified as type 1A, and the remaining 5% lacks defined markers of autoimmunity and 
therefore are classified as type 1B, also termed idiopathic [Todd, 1999]. Type 1 diabetes is 
observed in approximately 10% of patients with diabetes mellitus [Gilespie, 2006]. Type 1 
diabetes is a complex polygenic disorder. It cannot be classified strictly by dominant, 
recessive, or intermediate inheritance, making identification of diseases susceptibility or 
resistant gene difficult [Atkinson & Eisenbarth, 2001; Rabinovitch, 2000]. The lifetime of type 
1 diabetes risk for a number of the general population is often quoted as 0.4%. Eight-five 
percent of cases of type 1 diabetes occur in individuals with no family of the disease. 
Differences in risk also depend on which parent has diabetes. The risk increases to 1 – 2% if 
the mother has diabetes and intriguingly to 3 – 7% if the father has diabetes [Haller & 
Atkinson, 2005; Warram et al., 1988]. The sibling risk is 6% [Risch, 1987]. Monozygotic twins 
have a concordance rate of 30 to 50%, whereas dizygotic twins have a concordance rate of 6 
to 10% [Haller & Atkinson, 2005]. Disease susceptibility is highly associated with inheritance 
of the HLA (Human Leukocyte Antigen) alleles DR3 and DR4 as well as the associated 
alleles DQ2 and DQ8. More than 9% of patients with type 1 diabetes express either DR3DQ2 
or DR4DQ8. Heterozygous genotypes DR3/DR4 are most common in children diagnosed 
with type 1 diabetes prior to the age of 5 (50%) [Atkinson & Eisenbarth, 2001]. Individuals 
with the HLA haplotype DRB1*Q302-DQA1*0301, especially when combined with 
DRB*10201-DQA1*0501 are highly susceptible (10 – 20-fold increase) to type 1 diabetes. On 
the other hand, HLA class II haplotypes such as DR2DQ6 confer dominant protection [Todd 
& Wicker, 2001]. Individuals with the haplotype DRB1*0602-DQA1*0102 rarely develop type 
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1 diabetes [Peakman, 2001]. Candidate genes studies also identified the insulin gene as the 
second most important genetic susceptibility factor [Bell et al., 1984]. Whole genome screen 
has indicated that there are at least 15 other loci associated with type 1 diabetes [Concannon 
et al., 1998; Cox et al., 2001]. To date, no single gene is either necessary or sufficient to 
predict the development of type 1 diabetes. Although type 1 diabetes is likely a polygenic 
disorder, epidemiological pattern of type 1 diabetes suggests that environmental factors are 
involved [Dorman & Bunker, 2000]. 
4.1.3 Type 2 diabetes mellitus 
Type 2 diabetes mellitus, previously called non-insulin-dependent diabetes mellitus, is a 
complex heterogeneous group of metabolic disorders including hyperglycemia and 
impaired insulin action and/or insulin secretion. Current theories of type 2 diabetes include 
a defect in insulin-mediated glucose uptake in muscle, a dysfunction of the pancreatic ǃ-
cells, a disruption of secretory function of adipocytes, and an impaired insulin action in liver 
[Lin & Sun, 2010]. The etiology of human type 2 diabetes is multifactorial with genetic 
background and environmental factors of the modern world which favor the development 
of obesity. Several findings indicate that genetics is an important contributing factor. It has 
been estimated that 30 – 70% of type 2 diabetes risk can be attributed to genetics [Poulsen et 
al., 1999]. The lifetime risk of type 2 diabetes is about 7% in a general population, about 40% 
in offspring of one parent with type 2 diabetes, and about 70% if both parents have type 2 
diabetes [Majithia & Florez, 2009]. Patterns of inheritance suggest that type 2 diabetes is 
both polygenic and heterogeneous – i.e. multiple genes are involved and different 
combinations of genes play a role in different subsets of individuals [Doria et al., 2008]. 
Genetic research effort have led to the identification of at least 27 type 2 diabetes 
susceptibility genes [Staiger et al., 2009] and most recent genome-wide association studies 
have identified 20 common genetic variants associated with type 2 diabetes [Ridderstral & 
Groop, 2009]. Since skeletal muscle accounts for ~ 75% of whole body insulin-stimulated 
glucose uptake, defects in this tissue play a major role in glucose homeostasis in patients 
with type 2 diabetes [Bjornholm & Zierath, 2005]. Insulin resistance in skeletal muscle is 
among the earliest detectable defects in humans with type 2 diabetes [Mauvais-Jarvis & 
Kahn, 2000]. Type 2 diabetic patients are characterized by a decreased fat oxidative capacity 
and high levels of circulating free fatty acid [Blaak et al., 2000]. The latter is known to cause 
insulin resistance by reducing stimulated glucose uptake most likely via accumulation of 
lipid inside the muscle cell [Boden, 1999]. A reduced fat oxidative capacity and metabolic 
inflexibility are important components of skeletal muscle insulin resistance [Phielix & 
Mensink, 2008]. 
4.1.4 Gestational diabetes mellitus 
Gestational diabetes mellitus is defined as “carbohydrate intolerance with onset or first 
recognition during pregnancy” [Metzger, 1991]. This definition includes pregnancies in 
which the following occur: insulin therapy is required, diabetes persists after delivery, and 
diabetes may have been present, but not recognized, prior to the pregnancy [Avery & Rossi, 
1994]. Women at risk of type 2 diabetes are at risk of gestational diabetes mellitus [Cheung, 
2009]. Gestational diabetes mellitus is a heterogeneous disorder in which age, obesity, and 
genetic background contribute to the severity of the disease. Multiparous women have a 
very high prevalence of gestational diabetes mellitus [Wagaarachchi et al., 2001]. There has 
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been relatively little research in the area of gestational diabetes genetics [Watanabe et al., 
2007].There is evidence for clustering of type 2 diabetes and impaired glucose tolerance in 
families with gestational diabetes mellitus [McLellan et al., 1995] and evidence for higher 
prevalence of type 2 diabetes in mothers of women with gestational diabetes [Martin et al., 
1985]. The pathophysiology of gestational diabetes remains controversial. Gestational 
diabetes mellitus may reflect a predisposition to type 2 diabetes under the metabolic 
conditions of pregnancy or it may represent the extreme manifestation of metabolic 
alterations that normally occur in pregnancy [Butte, 2000]. Women with gestational diabetes 
have decreased insulin sensitivity in comparison with control groups. Gestational diabetes 
induces a state of dyslipidemia consistent with insulin resistance. During pregnancy, 
women with gestational diabetes do have high serum triacylglycerol concentrations but 
lower LDL-cholesterol concentrations than do healthy pregnant women [Koukkou et al., 
1996]. During pregnancy, gestational diabetes is associated with a number of complications 
for child. Because insulin does not cross the placenta, the fetus is exposed to the maternal 
hyperglycemia. The fetal pancreas is capable of responding to this hyperglycemia [Scollan-
Kolippoulos et al., 2006]. The fetus becomes hyperinsulinemic, which in turn promotes 
growth and subsequent macrosomia [Perkins et al., 2007]. Fetus born to mother with 
gestational diabetes has higher risk of developing macrosomia, neonatal hypoglycemia, 
hyperbilirubinemia, shoulder dystonia with its attendant risk of brachial injury and clavicle 
fracture, etc [Ecker et al., 1997; Hapo Study Group, 2008; Hod et al., 1991; Langer & Mazze, 
1988; Persson & Hanson, 1998]. These complications have been reported with varying 
frequency [Garner, 1995]. Additionally, there are some data that suggest an increase in fetal 
malformation and perinatal mortality [Sepe et al., 1985]. Cesarean sections are also more 
common, and gestational diabetes mellitus is associated with a higher risk of pre-eclampsia 
[Hapo Study Group, 2008, Persson & Hanson, 1998]. Infant exposed to maternal diabetes in 
uterus have and increased risk of diabetes and obesity in childhood and adulthood 
[Silverman et al., 1998]. Studies indicate that the magnitude of fetal-neonatal risk is 
proportional to the severity of maternal hyperglycemia [Langer & Conway, 2000]. 
Gestational diabetes is one of the most common complications in pregnancy occurring in 
2,2% - 8,8% of each year, dependent on the ethnic mix of the population and the criteria 
used for diagnosis.  
4.1.5 MODY 
MODY (Maturity onset diabetes of young) is a monogenic and autosomal dominant form of 
diabetes mellitus. Disease was described in 1974 – 1975 and since then newer gene 
mutations and subgroups of MODY have been identified [Tattersall, 1974; Tattersall & 
Fajans, 1975]. To distinguish MODY from type 1 diabetes tests need to be done to establish 
the absence of diabetes antibodies (anti-insulin, anti-islet, anti-glutamic acid decarboxylase). 
In obese people, the absence of insulin resistance, will differentiate it from type 2 diabetes. 
MODY presents in children, adolescent or young adults and may account for up to 5% of 
diabetes cases [Johnson, 2007]. MODY patients have a strong family history of diabetes, 
suggestive of a primary genetic cause [Fajans et al., 2001; Mitchell & Frayling, 2002]. MODY 
is caused by changes to a single gene and if either one of the parents carriers this gene they 
have a 50% chance of passing it on to their child. Disease progression in MODY is though to 
be largely independent of nongenetic factors other than time. A primary physiological 
defect caused [Fajans et al., 2001; Mitchell & Frayling, 2002]. Nine of genetic forms of MODY 
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have been identified to date, and these have been termed MODY 1 – 9. These rare diabetic 
disorders are associated with heterozygosity for mutations in single genes, including 7 
transcription factors (MODY 1, 3, 4, 5, 6, 7 and 9) and 2 metabolic enzymes (MODY 2 and 8). 
In some cases, there are significant differences in the activity of the mutant gene product 
that contribute to variations in the clinical features of the diabetes. 
4.1.6 Neonatal diabetes mellitus 
Neonatal diabetes mellitus is defined as insulin-sensitive hyperglycemia occurring in the 
first months of life, lasting for more than 2 weeks and required insulin for management 
[Shield, 2000]. It is rare, with an incidence of approximately 1 in 500 000 births [von 
Muhlendahl & Herkenhoff, 1995]. Neonatal diabetes mellitus is considered distinct from 
autoimmune type 1 diabetes, which manifests after the first 3 to 6 months of life [Hathout et 
al., 2000]. In this disease, antibodies to insulin or islet cells and other markers of 
autoimmune type 1 diabetes are absent. There are two separate forms of neonatal diabetes 
mellitus that vary in the length of insulin dependency in the premature stage of disease. In 
about 50% of cases of neonatal diabetes mellitus, diabetes is transient and resolves at a 
median age of 3 months (Transient Neonatal Diabetes Mellitus). The other 50% of cases of 
neonatal diabetes mellitus are permanent (Permanent Neonatal Diabetes Mellitus) [Neve et 
al., 2005]. The etiology of neonatal diabetes mellitus is genetically heterogeneous, producing 
abnormal development or absence of pancreas or islets, decreased ǃ-cell mass secondary to 
increased ǃ-cell apoptosis, and ǃ-cell dysfunction that limits insulin secretion [Aguilar-
Bryan & Bryan, 2008]. Transient neonatal diabetes mellitus is a form of neonatal diabetes 
that appears in the first six weeks of life and usually ends by 18 months. It is characterized 
by intrauterine growth retardation, dehydration, small gestational age at birth, and failure 
to thrive. Permanent neonatal diabetes mellitus can occur alone or as a larger genetic 
syndrome. In permanent neonatal diabetes mellitus, diabetes develops within days to 
months after birth and persists throughout life. Intrauterine growth retardation, 
hyperglycemia, sever dehydration, osmotic polyuria, and failure to thrive are all associated 
with permanent neonatal diabetes mellitus. 
4.2 Hypoglycemia 
4.2.1 Definition of hypoglycemia 
Normally, the body maintains the levels of sugar in the blood within a range of about 70 to 
110 mg/dL, depending on when a person last ate. In the fasting state, blood sugar can 
occasionally fall below 60 mg/dL and even to below 50 mg/dL and not indicate a serious 
abnormality or disease. This can be seen in healthy women, particularly after prolonged 
fasting. Hypoglycemia, also called low blood glucose or low blood sugar, occurs when 
glucose drops below normal levels. Hypoglycemia is defined arbitrarily as blood glucose of 
less than 50 mg/dL (2.8 mmol/L) with neuroglycopenic symptoms or less than 40 mg/dL 
(2.2 mmol/L) in the absence of symptoms [Carroll et al., 2003]. The clinical manifestations of 
hypoglycemia are nonspecific. Therefore, clinically significant hypoglycemia is 
characterized by Whipple’s triad: 1) symptoms of neuroglycopenia, 2) simultaneous blood 
glucose lower than 40 mg/dL (2.2 mmol/L), 3) relief of symptoms with the administration 
of glucose. All 3 criteria should be met to establish a diagnosis of hypoglycemia. 
Asymptomatic hypoglycemia with glucose levels as low as 30 mg/dL (1.7 mmol/L) can be 
seen during fasting in normal women and during pregnancy [Merimee & Tyson, 1974]. 
www.intechopen.com
 
Glucose Homeostasis – Mechanism and Defects 
 
237 
Asymptomatic patients may have artifactural hypoglycemia due to in vitro consumption of 
glucose by blood cell elements such as in leukemia or polycythemia [Carroll et al., 2003]. 
4.2.2 Signs and symptoms of hypoglycemia 
Because of the effectiveness of the normal defenses against falling plasma glucose 
concentrations, hypoglycemia is an uncommon clinical event, except in persons who use 
drugs that lower plasma glucose levels, to treat diabetes mellitus [Cryer, 2004; Cryer et al., 
2009; Guettier & Gorden, 2006]. According to Cryer and colleagues [Cryer et al., 2009], in 
healthy individuals, symptoms of hypoglycemia develop at a mean plasma glucose 
concentration of approximately 55 mg/dL (93.0 mmol/L). However, the glycemic threshold 
for this and other responses to hypoglycemia shift to lower plasma glucose concentrations in 
patients with recurrent hypoglycemia [Cryer, 2001 a, Cryer, 2009]. Documentation of 
Whipple’s triad established that a hypoglycemic disorder exists. In a person who does not 
have diabetes mellitus an unequivocally normal plasma glucose concentration during a 
symptomatic episode indicates that symptoms are not the result of hypoglycemia [Cryer et 
al., 2009]. The clinical manifestations of hypoglycemia are nonspecific. The central nervous 
system relies primarily on glucose for generation of cellular energy, but has reserves 
sufficient for only a few minutes and cannot synthesize glucose. Furthermore, studies have 
demonstrated that glucose is an obligate metabolic fuel for the brain under physiological 
conditions. It is to note, that glucose is not the only fuel that can be utilized by the brain. The 
noninjured brain can also utilize ketone bodies, particularly during starvation [Robinson & 
Williamson, 1980]. On the other hand, the brain cannot use fuels others than glucose during 
acute hypoglycemia [Cryer, 2001 a; Cryer, 2007; Wahren et al., 1999]. When the brain is 
deprived of its supply of glucose, serious neurological dysfunction occurs [Carroll et al., 
2003]. During severe hypoglycemia, glycogen stores appear to play a special role in 
maintaining brain function. Studies suggest that increasing brain glycogen stores protects 
neuronal activity [Wender et al., 2000]. Results obtained from human and animal studies 
showed that the most sensitive neuronal populations are the superficial layers of the cortex, 
the hippocampus, the caudate nucleus, and the subiculum [Auer et al., 1984; Auer et al., 
1985]. Hypoglycemia induces neuronal death [Lacherade et al., 2009]. The neuronal death 
resulting from hypoglycemia is not a straightforward result of energy failure but instead 
results from a sequence of events initiated by hypoglycemia [Such et al., 2007]. These events 
include activation of neuronal glutamate receptors [Nellgard & Wieloch, 1992], production 
of mitochondrial reactive oxygen species [Singh et al., 2004], neuronal zinc release [Assaf & 
Chung, 1984], and extracellular release of excitatory amino acids (glutamate and aspartate) 
[Engelsen et al., 1986]. Activation of postsynaptic glutamate receptor and postsynaptic zinc 
accumulation induce a variety of mechanisms leading to neuronal death [Patockova et al., 
2003; Singh et al. 2004]. According to Carroll and colleagues [Carroll et al., 2003], there are 4 
pathophysiologic mechanisms capable of exceeding the body’s counterregulatory capacity 
and causing severe hypoglycemia: excessive insulin effect, diffuse hepatic dysfunction, 
limited substrate for gluconeogenesis and excessive glucose consumption. More than one 
mechanism may be responsible, especially in ill patients. Symptoms of hypoglycemia are 
categorized as neuroglycopenic and neurogenic or autonomic. Symptoms of hypoglycemia 
may be nonspecific but tend to be similar for repeated episodes in the same individual. The 
symptoms associated with hypoglycemia are sometimes mistaken for symptoms caused by 
conditions not related to blood sugar. Unusual stress and anxiety can cause excess 
production of catecholamines, resulting in symptoms similar to those caused by 
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hypoglycemia but having no relation to blood sugar levels. Symptoms can being slowly or 
suddenly, progressing from mild discomfort to severe confusion or panic within minutes. If 
left untreated, hypoglycemia can get worse and cause confusion, clumsiness, or fainting. 
Severe hypoglycemia can lead to seizures, coma, and even death. General symptoms of 
hypoglycemia are: nausea, dizziness, collapse, weight gain. Neurogenic symptoms result 
from sympathoadreanl discharge triggered by hypoglycemia. They include sweating, 
tremor, palpitations, tachycardia, agitation, nervosity, hunger [Towler et al., 1993]. 
Symptoms linked to neuroglycopenia are direct result of the lack of brain metabolic energy. 
Neuroglycopenic symptoms occur at glucose levels of approximately 45 mg/dL and impair 
the ability of affected individual to take corrective action to abort severe hypoglycemia 
[Carroll et al., 2003]. These symptoms include impairment of consciousness, mental 
concentration, vision, speech, memory. Blurred vision, fatigue, seizures, paralyses, ataxia, 
loss of consciousness, unusual or bizarre behavior, and emotional liability [Cryer, 2008 a; 
Guettier & Gorden, 2006; McAulay et al., 2001; Ng, 2010; Towler et al., 1993]. Coma may 
result from values below 40 - 50 mg/dL [Ben-Ami et al., 1999], and death in extreme cases. 
Hypoglycemia can also happen during sleep. Some signs of hypoglycemia during sleep 
include crying out or having nightmares, finding pajamas or sheets damp from perspiration, 
feeling tired, irritable, or confused after waking up. The symptoms of hypoglycemia rarely 
develop until the level of sugar in the blood falls below 60 mg/dL of blood. Some people 
develop symptoms at slightly higher levels, especially when blood sugar levels fall quickly, 
and some do not develop symptoms until the sugar levels in their blood are much lower. 
The body first responds to a fall in the level of sugar in the blood by releasing noradrenaline 
(epinephrine) from the adrenal glands. Hormone stimulates the release of sugar from body 
stores but also causes symptoms similar to those of an anxiety attack: sweating, 
nervousness, shaking, faintness, palpitations, and hunger. Sometimes people who are 
hypoglycemic are mistakenly thought to be drunk. In adults and children older than 10 
years, hypoglycemia is uncommon except as a side effect of diabetes treatment. 
Hypoglycemia in people who not have diabetes is far less common than once believed 
[Cryer, 2008; Guettier & Gorden, 2006; Service, 1995; Service, 1999]. It can occur in some 
people under certain conditions such as early pregnancy, prolonged fasting, and long 
periods of strenuous exercise. Hypoglycemia can also result, however, from other 
medications or diseases, hormone or enzyme deficiencies, or tumors. 
4.2.3 Causes and types of hypoglycemia 
Two types of hypoglycemia can occur in people who do not have diabetes: reactive 
hypoglycemia, also called postprandial hypoglycemia, occurs within 4 hours after meals 
and fasting hypoglycemia, also called postabsorptive hypoglycemia, is often related to an 
underlying disease [Cryer, 2008]. This classification has been criticised for being unhelpful 
diagnostically. According to Servise [1995] some causes of hypoglycemia can present with 
both postabsorptive and postprandial (e.g. insulinoma). Other disorders can present with 
erratically occuring symptoms independent of food ingestion (e.g. factitous hypoglycemia). 
Patients with an insulinoma, who typically have postabsorptive hypoglycemia, may 
experience postprandial hypoglycemia, and post-gastric-bypass patients, who typically have 
postprandial hypoglycemia, may have symptoms when fasting. Indeed, some disorders, e.g. 
factitous hypoglycemia, are not readily classified as either postabsorptive or postprandial 
[Cryer et al., 2009]. Therefore, a more useful approach for clinicans is a classification based 
on clinical characteristics [Ng, 2010]. Symptoms of the both reactive and fasting 
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hypoglycemia are similar to diabetes-related hypoglycemia. Symptoms may include hunger, 
sweating, shakiness, dizziness, light-headedness, sleeping, confusion, dificulty speaking, 
anxiety, and weaknes. The average age of a patient diagnosed with an insulinoma is the early 
40s, but cases have been reported in patients ranging from birth to age 80 years [Garza, 2008].  
4.2.3.1 Reactive hypoglycemia (postprandial hypoglycemia) 
A diagnostic of reactive hypoglycemia is considered only after possible causes of low blood 
sugar have been rulet out. Reactive hypoglycemia with no known cause is a condition in 
which the symptoms of low blood sugar appear 2 to 5 hours after eating foods, especially 
when meals contain high levels of simple carbohydrates (as for example glucose). Reactive 
hypoglycemia refers to hypoglycemia caused by external influences, like diet and 
medication use. This type is more amenable to management or cure. Reactive hypoglycemia 
can be seen in patients who have had surgical removal of the stomach and in patients who 
had other surgigal procedures (gastrojejunostomy, vagotomy, pyloroplast). This type of 
hypoglycemia, alimentary hypoglycemia, is another form of hypoglycemia. In the absence 
of stomach, glucose in the meal is rapidly absorbed into the blood stream through the 
intestines, causing sudden hyperglycemia. In order to correct this sudden hyperglycemia, 
excessive amounts of insulin are released by the pancreas, which drives the blood glucose 
down, causing hypoglycemia. The reactive hypoglycemia in gastrectomy patients occurs 
early, usually within 1 hour after a meal. In heredity fructose intolerance and galactosemia, 
an inherited deficiency of a heaptic enzyme causes acute inhibition of hepatic glucose 
output when fructose or galactose is ingested. In patients with leucine sensitivity in 
childhood leucine provokes an exaggerated insulin secretory response to a meal and 
reactive hypoglycemia. Reactive hypoglycemia can occur when blood glucose falls, stores of 
glucose from the liver are exhausted and an individual chooses not to eat. The body 
gradually adjusts to this situation by using muscle protein to feed glucose to brain and fat to 
fuel the other body cells, tissues and organs, but before this adjustment takes place, an 
individual may experience symptoms of glucose deprivation to the brain. Reactive 
hypoglycemia seldom causes glucose levels to drop low enough to induce severe 
neuroglycopenic symptoms; therefore, a history of true loss of consciousness is highly 
suggestive of an etiology other than reactive hypoglycemia. Reactive hypoglycemia has 
been suggested to be more common in people who are insulin-resistant, and it may be a 
frequent precursor to type 2 diabetes. Therefore patients who have a family history of type 2 
diabetes or insulin-resistance syndrome, may be at higher risk of developing hypoglycemia. 
Reactive hypoglycemia often is treated successfully with dietary changes and is associated 
with minimal morbidity. Mortality is not observed. Reactive hypoglycemia is reported most 
frequently by women. It typically is in women aged 25 – 35 years. The average age of a 
patients diagnosed with an insulinoma is the early 40s, but cases have been reported in 
patients ranging from birth to age 80 years [Garza, 2009]. Idiopathic postprandial 
hypoglycemia is another form of reactive hypoglycemia [Ng, 2010]. It is a disorder in which 
autonomic and neuroglycopenic symptoms develop postprandially, accompanied by low 
plasma glucose [Brun et al., 2000]. This disease is due to various mechanisms, as for 
example: 1) high insulin sensitivity, 2) an exaggerated insulin response, either related to 
insulin resistance or to increased glucagon-like peptide 1, 3) renal glycosuria, 4) defects in 
glucagon response [Brun et al., 2000]. In idiopathic postprandial syndrome, autonomic 
symptoms, appear 2 – 5 hours after a meal. It is to note that plasma glucose concentration is 
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normal [Charles et al., 1981]. This phenomenon is due to enhanced catecholamine release 
following a meal or enhanced sensitivity to normal postprandial noradrenaline 
(norepinephrine) and adrenaline (epinephrine) release. This condition is also known as 
pseudohypoglycemia [Foster & Rubenstein, 1998].  
4.2.3.2 Fasting hypoglycemia (postabsorptive hypoglycemia) 
Fasting hypoglycemia, also called postabsorptive hypoglycemia, is diagnosed from a blood 
samples that shows a blood glucose level below 50 mg/dL after an overnight fast, between 
meals, or after physical activity. Fasting hypoglycemia occurs when the stomach is empty. It 
usually develops in the early morning when a person awakens. In otherwise healthy people, 
prolonged fasting (even up to several days) and prolonged strenuous exercise (even after a 
period of fasting) are unlikely to cause hypoglycemia. However, there are several conditions 
or diseases in which the body fails to maintain adequate levels of sugar in the blood after a 
period without food. Causes of fasting hypoglycemia include certain medications, alcoholic 
beverages, critical illnesses, hormonal dificiences, some kinds of tumors, and certain 
conditions occurring in infancy and childhood. Drugs, including some used to treat 
diabetes, are the most common cause of hypoglycemia. Many other drugs have been 
reported to cause hypoglycemia, as for example: salicylates, sulfa medications, pentamidine, 
quinine [Cryer, 2008; Malouf & Brust, 1985; Murad et al, 2009]. In people who drink heavily 
without eating, alcohol can block the release of stored sugar from the liver. The body’s 
break-down of alcohol interferes with the liver’s efforts to raise blood glucose. The alcohol 
directly interferes with heaptic gluconeogenesis, but not glycogenolysis. The energy 
required for metabolism of alcohol is diverted from the energy needed to take up lactate. 
Patients who drink alcohol may become hypoglycemic after 12 – 24 hour when the glycogen 
stores are depleted. Hypoglycemia caused by excessive drinking can be serious and even 
fatal. Some illnesses that affect the liver, heart, or kidneys can cause hypoglycemia. Liver 
insufficiency/failure from any cause may result in deficient glycogen stores or inadequate 
gluconeogenesis. In advanced liver failure, the defects may be severe enough to cause 
hypoglycemia. The kidneys have the capacity to produce glucose by gluconeogenesis. 
Isolated renal failure is rarely associated with hypoglycemia. More often, renal failure is 
associated with hupoglycemia in patients who are on insulin or insulin secretagogues as 
insulin is cleared by the kidney. Sepsis is other cause of hypoglycemia. In this case, 
hypoglycemia can occur due to decreased gluconeogenesis. Hormonal deficiencies may 
cause hypoglycemia in very young children, but rarely in adults. Certain endocrine 
deficiencies are associated with poor gluconeogenesis, poor glycogenolysis, or both. These 
include: adrenal insufficiency, hypopituitarism, isolated growth hormone deficiency, 
hypothyroidism, isolated glucagon deficiency, and sympathetic nervous system defects. 
Shortages of cortisol, growth hormone, glucagon or epinephrine can lead to fasting 
hypoglycemia. Mesenchymal tumors, hepatocellular carcinoma, adrenocortical tumors, 
carcinoid tumors, leukemia and lymphomas are nonislet cell tumors most commonly 
associated with hypoglycemia [Diaz et al., 2008; Guettier & Gorden, 2006; Jayaprasad et al., 
2006; Ng, 2010]. Although the pathogenesis is incompletely understood, it is belived that 
these tumors may secrete an insulin like substance that may be biologically active. An 
alternative hypothesis is that these tumors are so large that they require a significant 
amount of glucose the liver/kidney are unable to match. Insulinomas can cause 
hypoglycemia by raising insulin levels too high in relation to the blood glucose level. These 
tumors are rare and do not normally spread to other parts of the body. The estimated 
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incidence is 1 case per 250 000 patients-years [Service et al., 1991]. It is characterized by 
neuroglycopenia spells and occurs primarily in a fasting state, and only occasionally in a 
postprandial period [Kar et al., 2006]. Approximately 60% of patients with insulinoma are 
female. Insulinomas are uncommon in persons younger than 20 years and are rare in those 
younger than 5 years. The median age at diagnosis is about 50 years. In some people, an 
autoimmune disorder lowers sugar levels in the body by changing insulin secretion or by 
some other means. Hypoglycemia due to anti-insulin antibody is a rare disorder occurring 
in people often with a history of autoimmune disease [Ng, 2010]. Pregnancy is associated 
with lower glucose level because of decreased gluconeogenesis due to decreased substrate 
supply [Pugh et al., 2009]. Inborn errors of carbohydrate metabolism are rare and present 
during the first days of life [Gustafsson, 2009; Menhesha et al., 2007]. Infants present with 
fasting hypoglycemia, especially at night. Children rarely develop hypoglycemia and causes 
may include the following: brief intolerance to fasting, often during an illness that disturbs 
regular eating patterns, hyperinsulinism, which can result in temporary hypoglycemia in 
newborns, which is commons in infants of mather with diabetes, enzyme deficiencies that 
affet carbohydrate metabolism and hormone deficiencies.  
5. Hypoglycemia in diabetes mellitus 
Hypoglycemia occurring as a complication of therapy for diabetes is common [Chen, 2010; 
Ito et al., 2010; Swinnen et al., 2010]. Mild hypoglycemia occurs in more than half of all 
patients with diabetes who are in therapy. Hypoglycemia can occur as a side effect of some 
diabetes medications, including insulin and oral diabetes medications that increase insulin 
production. Rapid-acting insulin analogues may decrease the frequency of hypoglycemia 
associated with regular insulin administration. Insulin lispro has been shown to decrease 
postprandial glucose excursions and to result in less hypoglycemia in the postabsorptive 
state [Holleman et al., 1997]. Long-acting analogues, such as glargine, may decrease the 
frequency of hypoglycemia in both type 1 and type 2 diabetic patients [Pieber et al., 2000; 
Rosenstock et al., 2001]. Several studies have demonstrated a reduction in hypoglycemic 
events during continuous subcutaneous insulin infusion using a portable electromechanical 
pump when compared with multiple injection regimens [Pickup & Keen, 2002]. The effect of 
normal aging may contribute to the risk for severe hypoglycemia in older diabetic patients 
treated with sulfonylureas and insulin. Glycemic control in the pregnant diabetic women 
has major consequence on maternal and fetal morbidity and mortality. The strict control that 
is recommended during pregnancy leads to a high risk for hypoglycemia, the incidence 
reported as high as 72% in several studies [Coustan et al., 1986; Rosenn et al., 1995]. The 
majority of episodes occur during the first 20 weeks of gestation [Kimmerle et al., 1992]. 
Factors that may contribute to the occurrence of hypoglycemia during pregnancy include 
anorexia, changes in hormonal counterregulation or the development of altered 
hypoglycemic awareness [Bjorklund et al., 1998; Dagogo-Jack et al., 1993]. Exercise is an 
important mode of therapy in both type 1 and type 2 diabetes. High levels of insulin 
resulting from therapy may prevent the increased mobilization of glucose normally induced 
by exercise, and hypoglycemia may ensure. Exercise may cause immediate, early, and 
delayed hypoglycemia, particularly in type 1 diabetic patients and in patients with type 2 
diabetes on insulin or sulfonylurea therapy. In general, hypoglycemia during exercise tends 
to be less of problem in this population. Injection of insulin into the arm or abdomen 
decreases the hypoglycemic effect of exercise by 57% and 89%, respectively, in comparison 
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with injection of insulin into the leg [Koivisto & Felig, 1978]. Nonselective ǃ-blockers 
attenuate some components of the autonomic response to hypoglycemia and could increase 
the risk of hypoglycemia. In study with elderly diabetic patients, no significant impact on 
the rate of hypoglycemia could be associated with any particular class of antihypertensives 
[Shorr et al., 1997]. Although in general in type 2 diabetes mellitus there is less 
hypoglycemia risk versus type 1 diabetes mellitus, the frequency of hypoglycemia increases 
with increased diabetes and insulin treatment duration in type 2 diabetes mellitus [Cryer, 
2008 b]. Recent clinical trials have better quantified the risk of hypoglycemia in both type 1 
and type 2 diabetes [Leese et al., 2003; Pramming et al., 2000]. Severe hypoglycemia is 
operationally defined as an episode that the patient cannot self-treat, so that external help is 
required, regardless of the glucose concentration. Mild or moderate hypoglycemia refers to 
episodes that the patient can self-treat, regardless of the severity of symptoms, or when 
blood glucose levels are noted to be lower than 60 mg/dL. The incidence of mild or 
moderate hypoglycemia episodes is difficult to determine accurately because they are rarely 
reported, although they are common in insulin-treated patients [Gabriely & Shamoon, 2004]. 
Representative event rates for severe hypoglycemia in type 1 diabetes mellitus are from 62 
to 170 episodes per 100 patient-years [MacLeod et al., 1993]. These reported during 
aggressive insulin therapy of type 2 diabetes mellitus range from 3 to 73 episodes per 100 
patient-years [MacLeod et al., 1993]. When glucagon responses to hypoglycemia are 
deficient, epinephrine and autonomic warning symptoms become critical for the integrity of 
glucose counterregulation. Iatrogenic hypoglycemia attenuates the magnitude of adrenaline 
and autonomic symptom responses to a subsequent hypoglycemic episode [de Galan et al., 
2006]. Any hypoglycemia can provoke this phenomenon [Bolli et al., 1984; Davis & 
Shamoon, 1991; White et al., 1983]. Consequently, a downward vicious cycle of worsening 
counterregulation and recurrent hypoglycemia may ultimately lead to hypoglycemia 
unawareness. Clinical syndrome of hypoglycemia unawareness is defined as onset of 
neuroglycopenia before the appearance of autonomic warning symptoms and typified 
clinically by the inability to perceive hypoglycemia by symptoms [de Galan et al., 2006]. 
Patients with hypoglycemia unawareness are unable to manifest adequate behavioral 
defenses against developing hypoglycemia, therefore, hypoglycemia unawareness is also 
associated with a high frequency of severe iatrogenic hypoglycemia [Gold et al., 1994]. 
These patients are at a specifically high risk for severe disabling hypoglycemia (e. g. 
complicated by coma or seizures) that requires external assistance [Gold et al., 1994]. 
Hypoglycemia unawareness is generally though to be the result of reduced 
sympathoadrenal responses and the resultant reduced neurogenic symptom responses to a 
given level of hypoglycemia [Cryer, 2002; Hepburn et al., 1991]. According to de Galan and 
colleagues [de Galan et al., 2006], various terms are used for the combination of defective 
hormonal counterregulation and hypoglycemia unawareness, as for example: 
counterregulatory failure, hypoglycemia-associated autonomic failure (HAAF), and 
hypoglycemia unawareness syndrome. A reduced sympathoadrenal response is the key 
feature of hypoglycemia-associated autonomic failure and, thus, the pathogenesis of 
iatrogenic hypoglycemia in diabetes [Cryer, 2006]. According to suggestion described by 
Cryer [Cryer, 2005] “The concept of HAAF in type 1 [Dagogo-Jack et al., 1993] and advanced 
type 2 [Segel et al., 2002] diabetes posits that recent antecedent iatrogenic hypoglycemia 
causes both defective glucose counterregulation (by reducing epinephrine responses to a 
given level of subsequent hypoglycemia in the setting of absent decrements in insulin and 
absent increments in glucagon) and hypoglycemia unawareness (by reducing 
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sympathoadrenal and the resulting neurogenic symptom responses to a given level of 
subsequent hypoglycemia) a thus a vicious cycle of recurrent hypoglycemia”. Reduced 
sympathoadrenal actions play a key role in the pathogenesis of both defective 
counterregulation and hypoglycemia unawareness and thus HAAF in diabetes [Cryer, 
2004]. The mediators and mechanisms of HAAF are largely unknown [Cryer, 2005]. 
Different hypotheses are discussed [Cryer, 2001; Cryer, 2005; Cryer, 2006; Cryer et al., 2003; 
Cryer et al., 2009]. It is suggested that there are three causes of HAAF in diabetes: the 
originally recognized hypoglycemia-related HAAF, exercise-related HAAF, and sleep-
related HAAF [Cryer, 2004]. The clinical impact of HAAF is well established in type 1 
diabetes and it is less established in type 2 diabetes [Cryer, 2004]. Patients with iatrogenic 
hypoglycemia causes recurrent morbidity in most people with type 1 diabetes and many 
with type 2 diabetes, and it is sometimes fatal. Iatrogenic hypoglycemia often causes 
recurrent physical morbidity, recurrent or persistent psychosocial morbidity, or both and 
sometimes causes death [Cryer et al., 2003].  A direct relation between hypoglycemia and 
death has been proposed in the “dead-in-bed” syndrome [de Galan et al., 2006]. According 
to Maran et al. [1994] and Veneman et al. [1994], the dead-in-bed syndrome is rare disorder 
characterized by an unexpected death in young, previously healthy, tightly controlled 
patients with type 1 diabetes. Death in this syndrome is thought to be result of a fatal 
ventricular arrhythmia caused by hypoglycemia-induced lengthening of the QT interval 
[Bischof et al., 2004]. Corrected QT interval prolongation and increased QT dispersion have 
been demonstrated during acute-insulin-induced hypoglycemia in healthy subjects 
[Laitinen et al., 2008], in patients with type 1 and type 2 diabetes [Landstedt-Hallin et al., 
1999; Rothenbuhler et al., 2008] or during nocturnal hypoglycemia in patients with type 1 
diabetes [Murphy et al., 2004]. Myocardial cells can use either fatty acids or glucose 
oxidation as their source of energy [Stanley & Chandler, 2002]. Under normal conditions, the 
oxidation of fatty acids is prominent and in diabetic patients, the use of fatty acids is 
predominant [Lacherade et al., 2009]. During acute insulin-induced hypoglycemia or during 
nocturnal hypoglycemia in type 1 diabetes have been observed: cardiac rate and rhythm 
disturbances (tachycardia and brachycardia), and ventricular and atrial ectopy [Fisher et al., 
1990; Gill et al., 2009; Laitinen et al., 2008]. Ventricular repolarization abnormalities appear 
to be the main feature observed during episodes of hypoglycemia [Lacherade et al., 2009]. It 
is not yet known to what extent hypoglycemia contributes to mortality in type 2 diabetes 
mellitus [Lacherade et al. 2009]. Hospitalization is required in a minority of patients, usually 
for observation of neurologic signs during hypoglycemia, such as seizures, obtundation, 
coma, or focal neurologic signs. The need for hospitalization arises most commonly in 
diabetic patients, although hypoglycemia is frequently identified in patients with 
malnutrition and associated alcohol consumption, mental illness, or severe underlying 
medical illness [Hart & Frier, 1998]. Hypoglycemia occurs in 1.2% of hospitalized patients 
and is of somewhat more diverse etiology [Fischer et al., 1986]. Hypoglycemia in diabetes is 
fundamentally the result of treatments that raise insulin levels and thus lower plasma 
glucose concentration. 
5.1 Recommendations and prevention 
Cryer and colleagues [Cryer et al., 2009] recommend “1) that both the conventional risk 
factors and those indicative of compromised defenses against hypoglycemia be considered 
in a patient with recurrent treatment-induced hypoglycemia, and 2) with a history of 
hypoglycemia unawareness, a 2- to 3-wk period of scrupulous evidence of avoidance of 
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hypoglycemia”. Patients with diabetes become concerned about the possibility of 
developing hypoglycemia when the self-monitored blood glucose concentration is falling 
rapidly or is no greater than 70 mg/dL [Cryer et al., 2009]. Therefore diabetic patients need 
to be well informed about: the symptoms of hypoglycemia, the physiologic factors that 
come into play, the time course of the drugs they use; how to prevent and treat episodes of 
hypoglycemia, how to monitor their blood glucose levels, and the warning symptoms of 
hypoglycemia [Gabriely & Shamoon, 2004]. One of the most important things to prevent 
hypoglycemia is to educate the patient. Patients should always have a rapidly available 
source of glucose with them to treat hypoglycemia at the first sign of low glucose. Briscoe & 
Davis [2006] suggest that: 1) if blood glucose is < 70 mg/dL, give 15 – 20 g of quick-acting 
carbohydrate; 2) if test blood glucose 15 minutes after treatment is still < 70 mg/dL, re-treat 
with 15 g of additional carbohydrate; 3) if blood glucose is not < 70 mg/dL but is > 1 hour 
until the next meal, have a snack with starch and protein; 4) keep glucagon injection kit 
available for patients who are unconscious or unable to take in oral carbohydrate. It is to 
note, that insulin preparations have different onsets of action, times of peak effect, and 
effective duration of action. These differences affect both glycemic control and 
hypoglycemic episodes. Therefore, these factors must be considered when adjusting the 
treatment. A history of recurrent hypoglycemia should be investigated. 
5.2 Hypoglycemia in type 1 diabetes mellitus 
5.2.1 Pathophysiology 
Secretion of the three main counterregulatory hormones normally responsible for rapid 
reversal of hypoglycemia is severely disrupted in type 1 diabetes. Insulin secretion is either 
insignificant or absent and glucagon release during hypoglycemia is also impaired soon 
after the onset of diabetes. The plasma glucagon concentration does not increase as it should 
during hypoglycemia [Gerich et al., 1973]. This is because the pancreatic ǂ-cell glucagon 
secretory response to hypoglycemia is irreversibly lost [Cryer, 2001 b; Cryer et al., 2003]. The 
mechanism of the absent glucagon response to hypoglycemia that characterizes established 
type 1 diabetes is not known [Cryer et al., 2003]. Epinephrine is the main defense against 
hypoglycemia in patients with type 1 diabetes of > 5 years duration [Briscoe & Davis, 2006]; 
however, epinephrine release during hypoglycemia becomes progressively defective in type 
1 diabetes [Amiel et al., 1988; Bolli et al., 1983]. It is to note, that epinephrine secretory 
response to falling glucose levels is typically attenuated in type 1 diabetes [Amiel et al., 
1988; Dagogo-Jack et al., 1993]. HAAF in type 1 diabetes apparently results from antecedent 
episodes of mild hypoglycemia that further degrade the counterregulatory response 
[Dagogo-Jack et al., 1993]. Patients with type 1 diabetes already have a reduced 
counterregulatory response, therefore HAAF may play a role in the vicious circle of 
hypoglycemia begetting hypoglycemia. It is to note, that avoidance of hypoglycemia in type 
1 diabetes can improve the epinephrine response [Crauston et al., 1994]. Iatrogenic 
hypoglycemia in diabetes is the result of treatments that raise insulin levels and thus lower 
plasma glucose concentration. In type 1 diabetes iatrogenic hypoglycemia is the result of the 
interplay of relative or absolute insulin excess and compromised glucose counterregulation 
[Cryer, 2001]. It is suggested [Cryer, 2001] that absolute or relative insulin excess occurs 
when insulin or insulin secretagogue or sensitizer doses are excessive, exogenous glucose 
delivery is decreased, endogenous glucose production is decreased, glucose utilization is 
increased, sensitivity to insulin is increased, and insulin clearance is decreased. It is to note, 
that the conventional risk factors for iatrogenic hypoglycemia are based on the premise that 
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absolute or relative insulin excess is the sole determinant of risk [Cryer, 2001]. In patients 
with type 1 diabetes, treated with insulin, insulin levels are unregulated and do not decrease 
until the subcutaneous depot is depleted, even though the plasma glucose levels may have 
started to fall. Insulin injected subcutaneously enters the circulation much slower and 
therefore elevated insulin levels persist considerably longer. Differences in insulin 
absorption may explain why a dose of insulin to maintain normoglycemia at one time may 
be too much at other times and creating a risk for hypoglycemia.  
5.2.2 Frequency 
In type 1 diabetes, the Diabetes Control and Complications Triad reported 62 severe 
hypoglycemic episodes per 100 patient-years [The DCCT Research Group, 1993]. 
Population-based studies in northern Europe reported 100 to 160 patient-years [Leese et al., 
2003]. The average patient with type 1 diabetes suffers two episodes of symptomatic 
hypoglycemia per week, and one episode of temporarily disabling hypoglycemia (often 
with seizure or coma) per year [Cryer et al., 2009]. An estimated 2 to 4% of patients with 
type 1 diabetes die from hypoglycemia [Cryer et al., 2009]. In most instances, death cannot 
be attributed directly to hypoglycemia, but relates to the circumstances under which the 
hypoglycemic event envolved, e.g. in traffic, during swimming etc. 
5.3 Hypoglycemia in type 2 diabetes mellitus 
5.3.1 Pathophysiology 
Type 2 diabetes is characterized by a range of metabolic disorders: chronic hyperglycemia, 
declining ǃ-cell effectiveness resulting in the absence of first-phase insulin response to 
nutrient ingestion, insulin insensitivity in fat and muscle cells, and hepatic glucose 
production in the prandial state [Aronoff, 2004; DeFronzo, 2004]. The traditional primary 
defects responsible for the development and progression of type 2 diabetes are impaired 
insulin secretion, increased hepatic glucose production and decreased peripheral glucose 
utilization. Insulin secretion may be increased early in the course of type 2 diabetes, as the 
pancreas attempts to compensate for the elevated fasting plasma glucose concentration and 
underlying insulin resistance. Insulin resistance is a key pathologic defect that is 
characteristic feature of type 2 diabetes [DeFronzo, 2009]. The liver, muscle and adipose 
tissue are severely resistant to the action of insulin. The current type 2 diabetes disease 
model supports more aggressive treatment later in the course of disorder and less 
aggressive treatment in its earlier stages [Stolar, 2010]. Hypoglycemia is a major barrier to 
care for physicians and their patients with type 2 diabetes. Certain agents prescribed for 
type 2 diabetes significantly increase the risk of hypoglycemia, whereas others are 
associated with a lower occurrence of hypoglycemia [DeFronzo, 2010; Kushner, 2011]. 
Exogenous insulin preparations have all been associated with hypoglycemia. Injected 
insulin can produce absolute or relative insulin excess largely because of dosing and 
pharmacokinetics[Briscoe & Davis, 2006; Gabriely & Shamoon, 2004]. Oral antidiabetic 
medications can be a source of iatrogenic hypoglycemia in patients with type 2 diabetes. 
Sulfonylurea drugs enhance insulin secretion and are associated with hypoglycemia, 
especially in the elderly [Nathan et al., 2009]. Most reported cases of severe hypoglycemia 
were in patients taking chlorpropamide or glyburide [Gordon et al., 2009; Nathan et al., 
2009]. Sulfonylurea drugs can interact with other agents to cause severe hypoglycemia. For 
example, the additive or possibly synergistic effects during combined insulin and 
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sulfonylurea therapy account for an increasing number of such episodes. Metformin 
monotherapy is usually not associated with hypoglycemia. The frequency of severe 
hypoglycemia is lower with metformin than with sulfonylureas or insulin [Kushner, 2011; 
Gabriely & Shamoon, 2004]. Thiazolidinediones, that increase sensitivity of muscle, fat, and 
liver to endogenous and exogenous insulin, are associated with a low occurrence of 
hypoglycemia [Kushner, 2011]. However, these drugs, as monotherapy do not increase the 
risk for hypoglycemia, may cause hypoglycemia when insulin is used concomitantly 
[Gabriely & Shamoon, 2004]. ǂ-Glucosidase inhibitors slow the rate of polysaccharide 
digestion in the small intestine, are not associated with hypoglycemia [Nathan et al., 2009]. 
The incretins and dipeptidyl peptidase-4 (DPP-4) inhibitors increase insulin secretion via a 
glucose-dependent mechanism. These agents do not increase the risk for hypoglycemia. 
Nonsulfonylurea insulin secretagogues, such as glinide, stimulate insulin secretion, and are 
known to increase the risk of hypoglycemia [Kushner, 2011]. Counterregulatory responses 
to hypoglycemia have been investigated less systematically in type 2 diabetes than in type 1 
diabetes [Cryer, 2002; Gerich, 1988; Zammitt & Frier, 2005]. Although various 
counterregulatory hormone deficiencies have been described in type 2 diabetes, these were 
mostly mild, and epinephrine secretion was invariably preserved. The studies have shown 
that counterregulatory hormonal release occurs at higher blood glucose levels than in non-
diabetic subjects and patients with type 1 diabetes [Levy et al., 1998; Spyer et al., 2000]. On 
the other hand, in type 2 diabetes, residual ǃ-cell function largely preserves the first-line 
defence against hypoglycemia. Consequently, the glucagon response is retained, 
hypoglycemic risk is limited and further counterregulatory defects are prevented [Veneman 
et al., 1993]. 
5.3.2 Frequency 
Episodes of severe hypoglycemia are much less frequent in patients with intensively treated 
type 2 diabetes than with type 1 diabetes [MacLeod et al., 1993]. Obtained results indicate 
that 8 to 31% of insulin-treated patients with type 2 diabetes report having trouble in 
correctly identifying hypoglycemic events [Hepburn et al., 1990]. These patients have a nine 
fold higher risk for severe iatrogenic hypoglycemia than patients with normal hypoglycemic 
awareness [Bottini et al., 1997]. A study of patients with sulfonylureas and/or metformin 
observed that 20% of those taking sulfonylureas had experience symptoms of hypoglycemia 
in the preceding 6 months [Jennings et al., 1989]. Frequency of hypoglycemia in type 2 
diabetic patients in dependence on age, mode of therapy, nationality, sex etc. is described in 
details by Zammitt & Frier [2005]. To note, according to Rodbard and colleagues [Rodbard 
et al., 2009] “For some patients, the risk of hypoglycemia may warrant specific choices of 
therapy and reevaluation of therapeutic goals. These patients include those who have a 
duration of diabetes greater than 15 years and advanced macrovascular disease, 
hypoglycemia unawareness, limited life expectancy, or other serious comorbities”. 
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